Gene therapy, biotechnology, and clinical research by Solid Biosciences
NanoMosaic alliance positions Solid Biosciences Inc. to advance precision AAV capsid research
Solid Biosciences Inc. has entered into a co-marketing agreement with NanoMosaic, aiming to drive forward the development of next generation gene therapies. The partnership focuses on unlocking ...
Solid Biosciences joins Jefferies Global Healthcare Conference with CEO Bo Cumbo fireside chat
Solid Biosciences will participate in the Jefferies Global Healthcare Conference on June 3, where President and CEO Bo Cumbo is scheduled for a fireside chat at 7:35 AM ET. The company announced ...
Solid Biosciences Inc. spotlights Patrick González SGT-003 insights at major DMD conference
Solid Biosciences Inc. presented its next-generation gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) during a high-profile Clinical Trials session last week. Patrick ...
Solid Biosciences Inc. to host webinar on SGT-003 gene therapy for Duchenne
Solid Biosciences Inc. announced it will co-host a free community webinar with Defeat Duchenne on Wednesday, May 27, at 1:00 PM ET. The event will cover SGT-003, Solid Biosciences Inc.'s ...
Solid Biosciences Chief Medical Officer presents targeted therapy delivery approach at Boston biotech conference
Solid Biosciences announced that Chief Medical Officer Gabriel Brooks, M.D., will present at FierceBiotechWeek in Boston on Wednesday, May 13. Brooks will address one of genetic medicine’s ...
Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research
Solid Biosciences Inc. participated in and sponsored the SADS Foundation’s Challenging Cases in Inherited Arrhythmias Symposium and Reception last week. The company emphasized its commitment to ...
Solid Biosciences Inc. commits to industry and advocacy collaboration on Duchenne
Solid Biosciences Inc. will participate in the upcoming Team Joseph Info Stronger Together meeting next week. The company aims to engage with fellow industry partners and Duchenne muscular ...
Solid Biosciences Inc. advances SGT-212 gene therapy for Friedreich ataxia into human trials
Solid Biosciences Inc. is moving forward with SGT-212, a gene therapy designed to treat Friedreich ataxia, as one of the first therapies of its kind to enter human trials. The therapy stands out ...
Solid Biosciences Inc. to present new targeting strategies in gene therapy
Solid Biosciences Inc. will participate in the 2nd Annual Gene Therapy Symposium hosted by OSU Gene Therapy and Nationwide Children's Hospital this week, where the company will present on recent ...
Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration
Solid Biosciences Inc. is gaining attention for its involvement in the advancement of Friedreich ataxia (FA) research. The company recently featured its Chief Medical Officer, Dr. Gabriel ...
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials
Solid Biosciences’ Medical Director and Therapeutic Head, Neuromuscular, Matthew Harmelink, MD, will present new developments in the company’s FALCON gene therapy (SGT-212) Phase 1b study at ...
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial
Solid Biosciences Inc. announced encouraging interim clinical data from its ongoing Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, an investigational gene therapy targeting Duchenne muscular ...
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome
Solid Biosciences Inc. is sponsoring the XXIII International Conference on Duchenne and Becker Muscular Dystrophy, which takes place in Rome from February 27 to March 1. Key company ...
Solid Biosciences supports Jett Foundation RareDiseaseDay event
Solid Biosciences Inc. has announced its sponsorship of the Jett Foundation's #RareDiseaseDay event, titled ‘Advocating for Care Needs in Duchenne & Beyond’. The virtual panel is scheduled ...
